CJC-1295
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) andbinds to the GHRH receptor in the anterior pituitary gland. it is well known for its ability topreserve physiologic pulsatile secretion of GH while boosting GH levels. GHRP-6 is asynthetic analogue of ghrelin and binds to the growth hormone secretagogue receptor.
Research has shown that in combination, the two peptides work synergistically to substantially boost levels of GH. GHRP-6 acts as a baseline GH booster, increasing theset level of GH, in other words, GHRP-6 ensures that the lowest level that GH drops to ishigher than under normal physiologic conditions. CJc-1295 will then boost GH release ina pulsatile manner, using the new higherke baseline set by GHRP-6 as the trough andcreating proportionally elevated peaks[1], [2].
As an added benefit, research has shown that GHRP-6 stimulates appetite and improvessleep quality. increased food inta allows for better use of increased GH levels as thereis more raw material from which to build muscle, improve bone density, and promotegrowth. Sleep is the time during which animals are most receptive to the effects of GHand thus improved sleep quality helps to ensure that GH has the most impact onfunctions like wound healing and immune system regeneration. Both peptides have alsobeen linked to improved wound healing and protection of nervous tissue[3]-[6].
About The Author
The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. ELogan holds a doctorate degree from Case Western Reserve University School ofMedicine and a B.S.in molecular biology.
Scientific JournalAuthor
Márta Korbonits graduated in Medicine in Budapest and undertook her early clinicaltraining at the Internal Medicine Department of the Postgraduate Medical School,Budapest. She joined the Department of Endocrinology at St. Bartholomew’s Hospitalunder the mentorship of Professors Ashley Grossman and Michael Besser. Her MD andlater PhD studies contributed to the understanding of the effects of growth hormone secretagogues on hypothalamic hormone release and the nature and causes of pituitary tumorigenesis. She was awarded an MRC Clinician Scientist Fellowship and commenced studies that produced novel insights into ghrelin physiology and genetics. Her finding srelated to the regulation of the metabolic enzyme AMPK by ghrelin, cannabinoid andglucocorticoid opened a new aspect of hormonal requlation of metabolism. In 2008. MartaKorbonits was promoted to Professor of Endocrinology and Metabolism and since 2012has led the Centre of Endocrinology at Barts and the London School of Medicine. in 2016, Márta Korbonits was appointed a Deputy Head of the William Harvey ResearchInstitute. Professor Korbonits continues to integrate human studies alongside withlaboratory-based research and has pioneered several projects in translational medicine.
Márta Korbonits is being referenced as one of the leading scientists involved in theresearch and development of GHRP-6. In no way is this doctor/scientist endorsing oradvocating the purchase, sale, or use of this product for any reason. There is no affiliationor relationship, implied or otherwise, between PEPTIDE GURUS and this doctor. Thepurpose of citing the doctor is to acknowledge, recoanize, and credit the exhaustiveresearch and development efforts conducted by the scientists studying this peptide. MártaKorbonits is listed ini[7] under the referenced citations.
ReferencedCitations
[1]M. lonescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH)persists during continuous stimulation by CJC-1295, a long-acting GH-releasinghormone analog,”J.Clin.Endocrinol. Metab., vol.91, no.12,pp.4792-4797, Dec2006.[PubMed]
[2]S.L.Teichman, A. Neale, B.Lawrence, C.Gagnon, J.-P. Castaigne, and L. AFrohman, “Prolonged stimulation of growth hormone (GH) and insulin-like growthfactor l secretion by CJC-1295, a long-acting analog of GH-releasing hormone, inhealthy adults,”J.Clin.Endocrinol. Metab., vol. 91,no.3, pp.799-805, Mar. 2006[PubMed]
[3] Y. Mendoza Marí et al., “Growth Hormone-Releasing Peptide 6 Enhances theHealing Process and lmproves the Esthetic Outcome of the Wounds,” PlasticSurgery International, 2016.[Online]. Available:https://www.hindawi.com/journals/psi/2016/4361702/.[Accessed: 23-May-2019]
[4]M. Fernández-Mayola et al., “Growth hormone-releasing peptide 6 preventscutaneous hypertrophic scarring: early mechanistic data from a proteome study.Int. Wound J., vol.15,no.4, pp.538-546,Aug.2018.[PubMed]
[5]H.-J. Huang et al., “The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice,” Neuropharmacology, May 2019.[PubMed]
[6]N. Subirós et al..“Assessment of dose-effect and therapeutic time window inpreclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy,Neurol. Res., vol.38, no.3, pp.187-195, Mar. 2016.[PubMed]
7]Korbonits, Marta, and Ashley B.Grossman.“Growth Hormone-ReleasingPeptide and lts Analogues.” Trends in Endocrinology& Metabolism, vol. 6, no. 2,Mar.1995, pp.43-49 [PubMed]
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicalcondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
